The DEA Isn't Banning Kratom Again. It's Betting a Decimal Point Can Do What a Blanket Ban Couldn't.

He is forty-three in the case report, which is the only biography a case report gives you. He had opioid use disorder and had been managing it with kratom — the plant-based supplement, tea-colored powder in a capsule, sold at the gas station next to the energy shots — before he switched to something stronger: concentrated 7-OH tablets, 360 milligrams a day, because they produced a faster, more potent opioid-like effect and let him take less to get the same relief from cravings and withdrawal. Then he stopped. Forty-eight hours later he was in a hospital bed with the nausea, the cramping, the chills, and the restlessness that anyone who has come off an opioid will recognize immediately, being treated with the same medication — buprenorphine — that treats withdrawal from the drugs he’d been trying to avoid in the first place. A team of Chicago physicians and a clinical pharmacist from the University of Illinois Chicago College of Pharmacy published his case in the Journal of the American Pharmacists Association this spring, one of several such reports now appearing in clinical literature as 7-OH use has climbed. (JAPhA, 2026)

He is exactly the kind of person federal regulators say they are trying to protect, and exactly the kind of person who is about to lose the thing he was using to protect himself.

Washington has decided that how a molecule is made matters more than what it does for the person taking it — and it has given the public one week left to argue with a decimal point instead of a doctor.

That is the shape of the fight now playing out over 7-hydroxymitragynine, or 7-OH, the potent alkaloid found in trace amounts in the kratom plant and, increasingly, concentrated into tablets, shots, and gummies sold as a stronger, faster alternative to the leaf. On July 1, 2026, the Drug Enforcement Administration announced it intended to place 7-OH above a specific concentration into Schedule I — the same legal category as heroin and LSD, reserved for substances the government says have no accepted medical use and a high potential for abuse. (DEA, 2026) The Department of Health and Human Services opened a public comment period on exactly where that line should sit. That comment period, after a 15-day extension requested by a kratom researcher, closes on September 10, 2026. (Federal Register, 2026)

If you use kratom or 7-OH — to manage pain a doctor stopped treating, to stay off something worse, to get through a Tuesday without your hands shaking — this is not an abstract regulatory story. It is a countdown on a tool that is still, as of this writing, legal, sitting on your shelf, and about to become a felony to possess above a threshold nobody has finished arguing about.

A Molecule Split in Two, and a Deadline That Doesn’t Care Which Side You’re On

Start with what a “Notice of Intent” actually is, because the phrase does a lot of quiet work in every article about this. It is not a ban. It is the DEA telling the public it plans to use its emergency scheduling authority — a fast-track power that lets the agency temporarily control a substance for up to two years, with a possible third year, without going through the years-long formal rulemaking process a permanent ban would require. “Schedule I” is the government’s most restrictive category: no recognized medical use, high abuse potential, and criminal penalties for possession or distribution regardless of why you have it. Fentanyl, ironically, is Schedule II — doctors can prescribe it. Heroin, LSD, and, if this goes through, high-potency 7-OH are Schedule I, which means no prescription pad, no medical exception, full stop.

“Schedule I” is the government’s most restrictive category: no recognized medical use, high abuse potential, and criminal penalties for possession or distribution regardless of why you have it.

The DEA filed two of these notices on July 1. The first targets 7-OH itself, but not all of it: the proposed threshold is 0.050 percent by dry weight for the natural plant material, or 0.050 percent — roughly 1 milligram per unit — for anything “produced synthetically or derived from the kratom plant and further processed” into extracts, concentrates, edibles, or pressed pills. (Federal Register, July 2026) A second, separate notice places three other kratom-derived compounds — mitragynine pseudoindoxyl, MGM-15, and MGM-16 — into Schedule I outright, without a threshold exemption for trace amounts. (Federal Register, July 2026) DEA has said it will “exercise enforcement discretion” if only incidental trace amounts of that second group show up in an otherwise ordinary botanical kratom product — but has been explicit that discretion “does not create a legal exemption,” leaving the actual call to whichever officer or lab tests your product. (Kratom Science, 2026)

Whole-leaf kratom — the powder, the tea, the capsules sold as raw botanical — is explicitly not what either notice targets, and county governments implementing the change have said so plainly. (NACo, 2026) That’s the part regulators keep repeating, and it’s true as far as it goes. It’s also the part that does the least for the person who already switched to concentrated tablets or shots because the leaf wasn’t strong enough to touch their pain or their withdrawal anymore — which, per the industry’s own chief lobbyist, is precisely how this crisis got made. “The 7-OH industry created this crisis,” said Mac Haddow of the American Kratom Association, the trade group that has spent years defending kratom’s legality. “They manufactured or distributed high-potency opioid products, dressed them up as kratom, and then tried to force natural kratom consumers to pay the price.” (Pain News Network, 2026) It is a striking admission from the industry’s own advocate: the threshold exists because some manufacturers built a synthetic opioid product and marketed it under a supplement’s good name — and the DEA’s response, so far, is a percentage on a label rather than a crackdown on the labeling itself.

Washington Tried the Blunt Instrument Once. It Didn’t Survive Contact With the Public.

This isn’t the DEA’s first attempt at a kratom scheduling fight, and the last one is worth remembering in detail, because it’s the closest thing to a control group this story has.

In August 2016, the DEA announced its intent to temporarily place kratom itself — the whole plant, mitragynine and 7-OH together, no threshold, no carve-out for the leaf — into Schedule I as an emergency measure. The backlash was immediate and large: more than 142,000 people signed a White House petition opposing it, more than fifty members of Congress signed a bipartisan letter led by Representatives Mark Pocan and Matt Salmon calling the move “hasty,” and Senators Cory Booker, Kirsten Gillibrand, and Ron Wyden separately warned the DEA it hadn’t left time for public comment on a substance some were using to manage opioid withdrawal. Two months later, in October 2016, the DEA withdrew the notice entirely and opened a formal comment process instead — one that, in various forms, has run for most of a decade since. (Federal Register, 2016) (CPR News, 2016)

The 2026 approach is narrower on paper — a concentration threshold instead of a whole-plant ban, with natural leaf explicitly carved out from the start rather than exempted only after public outrage forced a retreat. Whether that makes it a smarter tool or simply the same overreach with better PR is the actual argument buried under all the percentages, and it is not a settled one. A threshold assumes manufacturers will read the threshold and comply with it. The 2016 fight assumed a blanket ban would survive contact with the people who’d have to live under it. Neither assumption has yet been tested at scale, which is a diplomatic way of saying nobody actually knows if this version works better — they just know it looks better going in.

The 2016 fight assumed a blanket ban would survive contact with the people who’d have to live under it.

What 7-OH Does Inside a Body, and Why the DEA and the Patient Are Describing the Same Molecule Differently

Strip away the acronyms and 7-OH is doing something pharmacologically specific, and it’s worth understanding exactly what, because the entire fight is downstream of it. 7-OH binds to the mu-opioid receptor — the same receptor site targeted by morphine, oxycodone, fentanyl, and, crucially, buprenorphine (the medication sold as Suboxone or Subutex, one of the two medications most addiction physicians consider gold-standard for opioid use disorder). Researchers classify 7-OH as a partial agonist at that receptor, the same technical category buprenorphine falls into: it activates the receptor enough to relieve pain and blunt withdrawal, but with a ceiling effect that, at least in theory, caps how far it pushes the same respiratory-suppression risk that makes full agonists like fentanyl so lethal. (Current Addiction Reports, 2026) That mechanism — chemically adjacent to a medication doctors already prescribe for exactly this purpose — is the entire reason pain patients and people self-managing withdrawal reach for it in the first place.

It’s also exactly what the DEA is warning about. The agency’s own language describes 7-OH as having “opioidergic activity, sharing a similar pharmacological profile to schedule II opioids like morphine,” carrying “a high abuse potential with safety risks, including tolerance, dependence, and respiratory depression, which are comparable to those of classic opioid analgesics.” HHS Secretary Robert F. Kennedy Jr. was blunter: “7-OH, MP, MGM-15, and MGM-16 are dangerous opioids that fuel addiction and put American lives at risk.” (Pain News Network, 2026) Both sides are looking at the same partial-agonist mechanism buprenorphine uses and drawing opposite conclusions from it — one side sees a safer opioid tool being sold without a prescription or a dose limit; the other sees an unregulated opioid, full stop, being marketed as a supplement. The clinical case reports piling up this year — hospitalizations for withdrawal from concentrated 7-OH, patients escalating to hundreds of milligrams a day, standard drug tests failing to even detect it — suggest neither read is wrong. The mechanism that makes 7-OH useful is the same one that makes it capable of doing real harm at high, unregulated, untracked doses.

That’s the part that doesn’t resolve cleanly, and it’s worth sitting with rather than picking a side too fast: a partial agonist at a controlled dose, prescribed and monitored, is buprenorphine — one of the two medications with the strongest evidence behind it for opioid use disorder. The same partial agonist, sold in a gas-station tablet at an unknown and unregulated concentration, with no monitoring and no dose ceiling anyone is enforcing, is a different product entirely, even though it’s the same molecule.

A Docket, a Deadline, and the Two Things Still Standing on the Other Side of It

The comment period closing September 10 is narrower than it might sound. HHS’s Office of the Assistant Secretary for Health has said explicitly that it is “not soliciting comments on any permanent scheduling decision, the general safety or utility of kratom-derived products, or other policy questions outside the scope of the threshold determination” — meaning the argument on the table isn’t “should 7-OH be legal,” it’s “where exactly should the concentration line sit.” (Kratom Science, 2026) The original 30-day window, which closed July 31, already drew more than 32,000 public comments to docket HHS-OASH-2026-0232 — an extraordinary volume for a threshold RFI, evidence of exactly how many people consider this personal rather than procedural. Neuroscientist and kratom researcher Dr. Michele Ross, who has studied more than 1,500 regular 7-OH consumers, requested the 15-day extension that pushed the deadline to September 10; the 7-HOPE Alliance, an advocacy group representing 7-OH manufacturers and users, called it an opening rather than a reprieve: “there is still a process ahead, and there is still an opportunity for science, evidence, and consumer voices to be heard.” (Pain News Network, 2026)

The comment period closing September 10 is narrower than it might sound.

Whatever the threshold ends up being, two things remain true on September 11 regardless of what regulations.gov says by midnight on the 10th. Natural kratom leaf — the plant, the powder, the tea — is not part of this scheduling action and isn’t going anywhere; nothing in either DEA notice touches it. And if what you’re actually managing is opioid withdrawal rather than pain, buprenorphine and methadone remain the two medications the FDA has approved and studied specifically for that purpose, available through a doctor, a clinic, or increasingly by telehealth — not a workaround, but the thing 7-OH is chemically trying to approximate without the dosing control or medical oversight that make the real version safer. SAMHSA’s National Helpline can point you toward either one, no judgment attached, 24 hours a day. None of that fixes what’s about to happen to concentrated 7-OH. It’s just what’s still standing on the other side of it.

Rize tracks how this kind of policy fight moves once the comment window closes, and keeps a running file on where kratom and other emerging substances sit under federal and state law as the rules shift under them. If you’re trying to figure out what comes next for you specifically rather than for the docket, Rize’s facility finder can point you toward providers who already know the difference between kratom, 7-OH, and the medications that treat withdrawal from both — because after September 10, the difference is going to matter more than it does today.

The man in the JAPhA case report isn’t named, and he never will be — that’s the deal a case report makes with the person it describes. But he is real, his withdrawal was real, and the tablets he used to manage a problem that started with pain and ended in dependence sit exactly in the concentration range this scheduling action is built to catch. Nobody arguing this docket, on either side, is arguing to make him better off. The DEA wants his product gone. The industry wants to keep selling it to him without whatever regulation forced the crisis. What nobody in the fight over the decimal point is quite proposing is what he actually needed well before he ended up in that hospital bed: somebody to ask what he was using and why, before he’d already escalated to 360 milligrams a day of a molecule the government hadn’t finished naming yet.